慢性阻塞性肺疾病发病机制的发展状况被引量：105

在线阅读下载PDF

导出

摘要慢性阻塞性肺疾病(COPD)是一种常见病、多发病,患病率和死亡率均高,其病情呈进行性发展,严重影响着患者的劳动能力和生活质量。世界卫生组织(WHO)资料显示:目前,COPD已成为全球第四位死亡原因,且逐年增加,预计到2020年将上升为全球第三位死亡原因和经济负担的第五位[1]。确切的病因还不清楚,发病机制已有多种学说,如:蛋白酶和抗蛋白酶学说、氧化损伤假说、免疫失衡和感染假说等。随着医学技术的发展目前对COPD的发病机制又提出了新的假说,即:肺炎衣原体慢性感染学说。本文结合相关文献,对COPD发病机制的发展状况作一综述如下。

作者余国辉陈敏

机构地区昆明医学院第二附属医院呼吸内科

出处《临床肺科杂志》 2010年第1期72-74,共3页 Journal of Clinical Pulmonary Medicine

关键词慢性阻塞性肺疾病(COPD) 病发病机制感染学说世界卫生组织死亡原因抗蛋白酶肺炎衣原体生活质量

分类号 R563.9 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献12

1王宋平,熊瑛,王鸿程.慢性阻塞性肺疾病的发病机制[J].临床肺科杂志,2005,10(4):521-522. 被引量：45
2GOLD. Global Strategy for the diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2006, www. goldcopd. org.
3黄斌,谢灿茂.慢性阻塞性肺疾病发病机制研究进展[J].广东医学,2003,24(6):666-668. 被引量：9
4揭志军,杨文兰.α_1-抗胰蛋白酶临床应用的前景[J].国外医学（呼吸系统分册）,1999,19(4):192-194. 被引量：10
5刘清敏,刘景艳.炎症细胞与COPD发病机制的关系[J].中原医刊,2004,31(19):39-41. 被引量：12
6张劲农.呼吸道黏膜防御机制与慢性阻塞性肺部疾病[J].华中医学杂志,2006,30(5):375-377. 被引量：3
7Bals R, Hiemstra PS. Innate immunity in the lung:how epithelial cells fight against respiratory pathogens. Eur Respir J,2004,23 (3) : 327.
8Pilette C, Ouadrhiri Y, Diamanche F, et al. Secretory component is cleaved by neutrophil serine proteinases but its epithelial production is increased by neutrophils through NF2 kappa B2 and p38 mitogen activated protein kinase dependent mechanisms. Am J Respir Cell Mol Biol,2003,28(4) :485.
9Chin CL, Manzel LJ, Lehman EE, et al. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. Am J Respir Crit Care Med ,2005,172( 1 ) :85.
10Ogawa E, Elliott W M, Hughes F, et al. Latent adenoviral infection induces production of growth factors relevant to airway remodeling in COPD. Am J Physiol Lung Cell Mol Physiol,2004,286 (1) :L189 - 197.

二级参考文献88

1Snider GL. Nosology for our day:it's application to chronic obstructive pulmonary disease. Am J Respir Crit Care Med,2003 ,167 :178 ～ 683.
2Finlay GA,ODriscoll LR, Russell KJ,et al. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med, 1997,156:240 ～ 247.
3Muley T, Wiebel M,Schulz V,et al. Elastinlytic activity of alveolar macrophages in smoking - associated pulmonary emphysem. Clin Invest,1994,72:269 ～ 276.
4Eidelman DH,G hezzoh,Kin WD,et al. The destruction index and early lung destruction in smokers. An Rev Respir Dis,1991,144:156 ～ 159.
5Ofulue AF, KOM. Effects of depletion of neutrophils of macrophages on development of cigarrete smoke - induced emphysema. Am J Physion,1999,27 :L97 ～ L105.
6Sinder GL. Emphysema:the first two centries;Parts Ⅱ . Am Rev Respir Dis, 1992,146:1615 - 1622.
7Saetta M, Di Stefano A,Turato G, et al. CD8 + T - lamphocytes in the peripheral airways of smokers with chronic pulmonary disease. Am J Respir Crit Care Med, 1998,157: 822 ～ 826.
8Juanita H J. Vernooy, Mieke A, Dentener,et al. Long - term Intratracheal lipopolysaccharide exposure in mice result in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol,2002,26:152～159.
9Majo J Chezzo H,Cosio MG Lymphocyte population and apoptosis in the lungs of smokders and their relation with the emphysema. Eur Respir J,2001,17:946 ～ 953.
10Huninghake GW,Crystal RG Cigarette smoking and lung destruction:accumulation of neutrophils in the lung of cigarette smokers. Am Rev Respir Dis, 1983,128:833 ～ 838.